CELG - CELG Stock is Up 45% YTD: What Should You Know?
CELG stock is currently on a good run of good news in 2019 after a few years of bad news from Celgene Corporation (NASDAQ:CELG).
In May, the company secured US Food and Drug Administration approval for a combination of Rituxan and Revlimid, which is a second-line follicular lymphoma and marginal zone lymphoma treatment. The FDA granted the company approval for Otezla in June for treatment of Behcet’s disease and on Friday the company received approval for Inrebic in the treatment of myelofibrosis.
FDA Approval of InrebicFollowing the approval of Inrebic by the FDA, ...
Get the latest stock market news on StreetSignals. Follow public companies and get free stock research reports and stock market analysis data and stock tips.
All content provided by StreetSignals is subject to our Terms Of Use and Disclaimer.